A randomized,double blind,placebo controlled,three group study to evaluate the comparative efficacy and safety of Curcuma caesia and Forskolin and Curcuma caesia for weight management in obese patients.

Sami Labs Limited0 个研究点目标入组 36 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous six months.
•2 Pathophysiologic or genetic syndromes associated with obesity like Cushingâ??s syndrome, Turnerâ??s syndrome, Praderwilli syndrome.
•3 Patients with evidence of malignancy.
•4 History of poorly controlled Diabetes Mellitus. Glycosylated haemoglobin greater than 10 percent.
•5 Patients on prolonged greater than 6 weeks medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
•6 Symptomatic patient with clinical evidence of Heart failure.
•7 History of HIV and other viral infections.
•8 Prior surgical therapy for obesity.
•9 History of hypersensitivity to any of the herbal extracts or dietary supplement.
•10 Pregnant or lactating woman.
•11 Patients who have completed participation in any other clinical trial during the past six months.
•12 Any other condition which the Principal Investigator thinks may jeopardize the study.

发起方

Sami Labs Limited